CNBX Pharmaceuticals Inc. Financial Ratios
CNBX|FY2025 SEC 10-K data
Includes DuPont ROE decomposition, profitability margins, liquidity ratios, solvency indicators, and earnings quality analysis. All ratios calculated from FY2025 SEC 10-K data.
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -1304.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
DuPont ROE Decomposition (FY2025)
Return on Equity
-
Profit Margin
-
Net Income / Revenue
Asset Turnover
0.00
Revenue / Total Assets
Equity Multiplier
-0.01
Total Assets / Equity
Profitability
Gross Margin
-
Operating Margin
-
EBITDA
-$274,157
EBITDA Margin
-
Liquidity
Current Ratio
0.01
Quick Ratio
0.01
Solvency
Interest Coverage
-4.30
Efficiency
Asset Turnover
0.00
Inventory Turnover
-
Days Sales Outstanding
-
As of FY2025 · SEC 10-K · Updated Jun 29, 2026
Earnings Quality
Accrual Ratio
-572.8%
+864.1pp YoY
Earnings are primarily supported by operating cash flow.
This metric is for informational purposes only and does not constitute investment advice. Data sourced from SEC EDGAR filings; updates may be delayed.